Rigel Pharmaceuticals Inc
F:RI2A
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
R
|
Rigel Pharmaceuticals Inc
F:RI2A
|
US |
|
B
|
Banco Santander SA
DUS:BSD2
|
ES |
|
B
|
Barclays PLC
F:BCY2
|
UK |
|
Galapagos NV
OTC:GLPGF
|
BE |
|
ActiveOps PLC
F:95D
|
UK |
Wall St Price Targets
RI2A Price Targets Summary
Rigel Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for RI2A is 21.66 EUR with a low forecast of 15.92 EUR and a high forecast of 30.92 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is RI2A's stock price target?
Price Target
21.66
EUR
According to Wall Street analysts, the average 1-year price target for RI2A is 21.66 EUR with a low forecast of 15.92 EUR and a high forecast of 30.92 EUR.
What is the Revenue forecast for Rigel Pharmaceuticals Inc?
Projected CAGR
-2%
Over the last 14 years, the compound annual growth rate for Revenue has been 34%. The projected CAGR for the next 8 years is -2%.
What is the Operating Income forecast for Rigel Pharmaceuticals Inc?
Projected CAGR
0%
The compound annual growth rate for Operating Income over the next 8 years is 0%.
What is the Net Income forecast for Rigel Pharmaceuticals Inc?
Projected CAGR
-16%
The compound annual growth rate for Net Income over the next 8 years is -16%.
